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ABSTRACT 
INTRODUCTION: No therapeutic approach has significantly impacted the progression of 
diabetes. As early improvement of glicaemic control is observed after bariatric surgeries, there 
is currently a search for surgical procedures that can promote euglycemia also in non-obese 
patients. Glicaemic control can be achieved by increasing the blood concentration of GLP-1, a 
hormone produced by L cells that are more densely concentrated in the terminal ileum. The 
interposition of ileal segment to a more anterior region (proximal jejunum) can promote a 
greater stimulation of the L cells by poorly digested food, increasing the production of GLP-1 
and reflecting on glicaemic control.   
AIMS: To investigate long-term histological modifications of intestinal mucosa of rats 
submitted to interposition of ileum segment to a proximal region (jejunum).  
METHODS: Forty 8-week old male Wistar-EPM1 rats (Rattus norvegicus albinus) were 
randomly distributed into 3 groups: the Interposition Group (IG) was subjected to ileal 
interposition, the Sham Group (SG) was subjected to sham operations, and the Control Group 
(CG) was not subjected to surgery. All animals were followed until the 60th postoperative day 
(8 postoperative week) when they were euthanized. Segments of jejunum and ileum from all 
groups were collected and analyzed by optical microscopy and immunohistochemistry.  
RESULTS: No structural nor histological changes in intestinal L cells in the interposed intestinal 
segment and other intestinal segments were noted after ileal interposition surgery.  
CONCLUSION: As L cells endocrine characteristics were likely maintained, the use of metabolic 
surgical techniques for the treatment of metabolic diseases, especially diabetes, seems to be 
justified. 
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1. INTRODUCTION 
Diabetes is one of the most common chronic diseases and a growing global epidemic 
(Danaei et al., 2011).1 Type 2 diabetes (T2D) is a serious metabolic disease characterised by 
high glucose levels. Complications from T2D usually result in poor quality of life, disability, and 
early death.2 Despite efforts to control glycaemia in diabetes patients, no therapeutic 
approach has significantly impacted the progression of this disease (Tahrani et al., 2010).3 
There is, however, a simple and reversible surgical procedure that might become a valid 
therapeutic alternative in non-obese patients. This procedure, isolated ileal interposition (III), 
results in a dramatic increase in the incretin glucagon-like peptide 1 (GLP-1). 
Epidemiology and aetiopathogenesis of diabetes  
In 2000, diabetes caused the death of about three million people.4 In 2010, the number of 
affected individuals was approximately 285 million, and this number is projected to increase 
54% by 2030. A much greater increase in the number of adults with diabetes is projected in 
underdeveloped countries than in developed countries: the number of affected individuals is 
projected to increase approximately 70% in underdeveloped countries and 20% in developed 
countries.1 T2D, also known as non-insulin-dependent diabetes, is responsible for 90% to 95% 
of diabetes cases.5 
T2D is a progressive heterogeneous disease that mainly involves peripheral insulin 
resistance and gradual dysfunction of pancreatic beta cells.2,6 It develops when pancreatic 
islets can no longer maintain insulinaemia at levels sufficient to overcome peripheral tissue 
resistance. Throughout the course of the disease, diabetes passes through intermediate 
stages. Initially, diabetes is treated only with modifications in lifestyle and specific diet. Later in 
the disease, patients are treated with drugs that promote insulin secretion. As insulin 
deficiency unavoidably increases, however, the combination of therapeutic oral agents often 
fails to control hyperglycaemia efficiently, and the use of insulin is eventually required.6-9 
In the long run, patients with T2D have an increased risk of complications that are a 
substantial cause of morbidity and mortality, including macrovascular disease, nephropathy, 
retinopathy, and neuropathy.10 Further complications of diabetes include ischemia of the limbs 
resulting in amputation, dental problems, and pregnancy disorders.5 The risk of developing 
diabetes-associated complications is related to the duration of diabetes and the level of 
glycaemic control.11 
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Although 90% of T2D cases can be attributed to excessive weight,12 its incidence is growing 
among individuals with body mass index (BMI) in the normal and overweight ranges.13,14 
Treatment of diabetes 
T2D is a multifaceted condition requiring an integrated and individualised approach to 
each patient’s care that can prove quite challenging (Freeman, 2010).15 Treatment must 
initially be based on substantial lifestyle changes, including diet adjustment and regular 
physical activity. In most patients, these behavioural measures eventually do not suffice to 
keep glycaemia within appropriate levels, and oral antidiabetic agents are added.17 Currently, 
there are several drug classes with different mechanisms of action that might be used singly or 
in various therapeutic combinations.16 Many patients eventually require combinations of two 
or more oral drugs.17-19 Despite these treatments, glycaemia increases over time as the disease 
progresses, requiring the use of insulin in combination with oral agents and eventual full 
insulinisation. Although these interventions might decrease peripheral blood glycaemia, none 
of these actions is effective in stopping disease progression.9 Intensification of insulin therapy 
is the most appropriate intervention used to attempt to achieve normoglycaemia and reduce 
complications through early, strict, persistent, and effective control of glycaemia.16,20,21 Thus, 
insulin is currently the only effective conservative therapeutic option for achieving metabolic 
control.6,7,22 
However, the use of external insulin is not easy to manage. Attaining optimal glicemic 
levels, i.e., glycaemia levels as close as possible to those of a non-diabetic individual23 in order 
to prevent complications, still poses a major challenge in clinical practice.2,21 Due to the 
limitations of most of the available therapeutic measures, only a small fraction of the diabetic 
population meets therapeutic goals.23 These limitations include poor compliance with diets, 
resistance to physical exercise programmes, limited efficacy and significant side effects of 
current therapeutic agents, delays in insulin therapy onset, and patient aversion to the 
multiple parenteral injection regimes required for the administration of insulin.21-24 Successful 
insulin therapy requires accurate information, motivation, high socioeconomic and cultural 
levels, high adherence and learning ability, availability of resources, and participation of and 
support by a multiprofessional team. 
Some antidiabetic drugs accelerate beta cell apoptosis,2 whereas others reduce bone 
mineral density and promote weight gain due to volume expansion and oedema, potentially 
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causing or exacerbating heart failure and triggering ischemic cardiac events.17,18 Some insulin 
analogues are associated with a more physiological pattern of recovery; these drugs are more 
flexible to use and convenient to prescribe, and they allow greater freedom in diet while still 
providing improved quality of life.6,7,25Formulations eliminating the need for subcutaneous 
injections might correct some limitations of typical insulin therapy, thus improving glicemic 
control and increasing patient quality of life.21 Some formulations that allow non-invasive 
administration of insulin are in the testing phase, including the inhalable insulin powders 
Exubera (Pfizer), Technosphere (MannKind), Aerdose (Aerogen), BAI (Kos), Alveair (Coremed), 
and Bio-Air (BioSante). Therapy selection must take into account tolerability, non-glycaemic 
effects of antidiabetic agents, effects on associated comorbidities, and cost (Stolar et al., 
2008).17  
The limitations of conventional treatments that fail to preserve pancreatic beta cell 
function over time have resulted in a critical need to find new means to attain appropriate 
glycaemic control and avoid or delay the need for additional measures (Hansen et al., 2010).2 
Thus, antidiabetic treatments seeking to preserve beta cell function and integrity and halt T2D 
progression are clearly needed.8 More effective measures based on the disease 
aetiopathogenesis are necessary; these measures must control both fasting and postprandial 
glycaemia.22 
A new approach to T2D treatment involves the use of therapies based on incretins 
such as dipeptydil peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists, which are GLP-1 
analogues and bind to GLP-1 receptors on pancreatic beta cells to inactivate them.2,3 Both 
groups of drugs have proven safe and effective in reducing glycaemia and have yielded 
favourable effects regarding weight, lipid profile, and blood pressure.9,17,26-28 Both are 
associated with insulin release and glucose-dependant glucagon suppression with consequent 
low hypoglycaemia risk. Experimental studies showed that these therapies prolong the 
survival, delay the dysfunction, and promote the regeneration of pancreatic beta cells and thus 
theoretically hold the potential to halt T2D progression.3,9,28 
Although these studies have demonstrated the therapeutic promise of DPP-4 and GLP-
1 analogues, the high cost of these new agents and the lack of studies on their long-term 
safety must be considered. Nausea, headache, acute pancreatitis, upper airway infection, 
depression, severe hypoglycaemia, and skin allergic reactions have been reported with the use 
of these drugs. Some individuals also exhibit moderate reduction of glycated haemoglobin 
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levels when compared to patients treated with insulin and older agents. Moreover, the 
development of carcinomas has been associated with the use of these agents in guinea pigs; 
however, this finding has not been confirmed in humans.18,19,28 
In addition to the wide variety of pharmacological options for multidisciplinary 
treatment aimed at weight loss and glycaemic control, bariatric and metabolic surgical 
techniques can be included among the therapeutic approaches to T2D and insulin resistance. 
These surgical interventions have been shown to provide long-term control of T2D.29,30  
Surgical interventions in non-morbidly obese patients (BMI < 35) 
Bariatric surgery can improve and eventually completely reverse obesity-associated 
comorbidities in 70% to 100% of patients,31 thus increasing their life expectancy,32 partially 
reversing hypothalamic dysfunction, and increasing the anti-inflammatory activity of the 
cerebrospinal fluid.33 
Improved glycaemic control is observed months after adjustable gastric band surgery, 
and improvement is faster and more complete with ROUX-en-Y bypass. Both strategies can 
improve or even cure T2D, potentially through different mechanisms (Meijer et al., 2011).34 
Vertical gastrectomy with or without contention ring and Roux-en-Y gastrojejunal bypass – 
thought to be the gold standard surgical intervention in the treatment of morbid obesity – are 
known to achieve the goals of weight loss and control of comorbidities and to maintain these 
goals over time.35 This control of comorbidities is usually attributed to body mass reduction; 
however, a potentially glycaemia-controlling endocrine effect has been observed even before 
any significant weight loss.36 After gastrojejunal bypass, levels of substances directly secreted 
by the bowel such as GLP-1 were found to be elevated in the peripheral blood; these 
substances can stimulate insulin production by pancreatic beta cells, facilitate insulin-mediated 
glucose transport into cells, and induce a feeling of satiety.37 
Roux-en-Y gastrojejunal bypass favours the stimulation of GLP-1-producing cells by 
foods arriving at the distal portions of the small intestine incompletely digested, as food transit 
is diverted to the proximal jejunum.38 Jejunal bypass and other highly effective bariatric and 
metabolic surgical interventions deliver nutrient-rich chyme to the distal bowel earlier than 
normal. Its arrival directly to the ileum activates a negative feedback mechanism known as the 
“ileal brake”,39 which involves neuronal and endocrine mechanisms that influence stomach 
voiding, intestinal motility, and satiety.40 
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As early as 1998, it was already thought that T2D might be an anterior bowel disease.41 
Currently, several clinical, physiological, biological, anthropological, epidemiological, 
anatomical, and evolutionary lines of evidences together with surgical results have confirmed 
that the proximal small intestine – whose size was appropriate for our ancestral environment – 
might have become too large due to the modern industrialised diet. Consumers of a rich and 
modified modern diet developed a much larger anterior intestine (jejunum) than desired. A 
shorter jejunum prevent ingested food from being fully absorbed in the proximal portion of 
the intestine, allowing it to arrive at the distal intestine (ileum) almost in natura in order to 
stimulate L-type endocrine cells to produce substances such as GLP-1 that promote insulin 
production by the endocrine pancreas, facilitate glucidic metabolism in peripheral tissues, and 
induce satiety through selective hypothalamic inhibition.42 
The genesis of disruptions in glucose metabolism involves a multifaceted range of 
intimately intertwined factors. Of these factors, hormones are the most significant; of 
particular interest is GLP-1, which is produced by enteroendocrine L-cells of the small intestine, 
which are more densely concentrated at the terminal ileum.32 GLP-1 is produced by tissue-
specific post-translational processing of its precursors, namely, the peptide proglucagon, by 
pro-hormone convertase enzymes.43 Post-translational modifications of the glucagon gene give 
rise to five different products in the bowel: glycentin, oxyntomodulin (OXM), intervening 
peptide-1 (IP-1), GLP-1, and GLP-2.44 Proglucagon is processed in bowel L-cells by PC1/3 pro-
hormone convertase.43 GLP-1 secretion occurs in response to stimuli generated by nutrients 
with an incretin effect.45 Incretins are hormones secreted into the blood circulation by the 
gastrointestinal tract in response to intake of certain nutrients. This results in increased insulin 
production and consequent glucose uptake. GLP-1 has well-defined functions, such as 
stimulation of glucose-dependent insulin secretion, upregulation of insulin gene transcription, 
induction of Langerhans islet beta cell neogenesis and proliferation, inhibition of beta cell 
apoptosis, increased phenotypic differentiation of beta cells, stimulation of somatostatin 
production, and reduction of glucagon production.46,47 
Advances in neurogastroenterology have provided a better understanding of 
gastrointestinal physiology. Therefore, bariatric surgery intervention modalities evolved into 
the current mixed procedures that take into account neurohormonal and metabolic factors in 
addition to restriction and dysabsorption features. Thus, the term baroendocrine surgery is 
increasingly used, especially in the treatment of T2D.38,40 Currently, mixed (restrictive and 
dysabsorptive) bariatric surgery is the most efficacious treatment in patients with morbid 
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obesity, resulting in significant improvement of associated comorbidities (Melissas, 2008).49 In 
studies of these interventions, enhanced GLP-1 release and improved glycaemic control have 
been observed even before significant weight loss, demonstrating that the control of diabetes 
might be related to hormonal effects secondary to the surgical technique performed.47,50 
Isolated ileal interposition 
In the early 1980s, enhanced GLP-1 release had already been shown to suffice for body 
weight control in obese rats treated with the interposition of a 5- or 10-cm terminal ileum 
fragment.51 The effects of this surgery are illustrated in Figure 1. 
 
 
Figure 1. Effects of ileal interposition on glucose control. (1) Dietary nutrients enter the bowel lumen and stimulate 
neuroendocrine cells causing (2) early and long-lasting GLP-1 release, (4) which will affect gastrointestinal motility 
and stomach voiding. (5) GLP-1 is an incretin and will also mediate insulin secretion and endocrine pancreas 
protection.
52
 
 
Another study in rats showed hypertrophy of transposed ileum together with 
increased serum GLP-1 levels.53 In humans, GLP-1 increased after jejunoileal and 
biliopancreatic bypass in morbidly obese individuals.54 Another study published in 1998 
showed that patients exhibited high levels of GLP-1 even 20 years after jejunoileal bypass.55 
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Together with a study published in 1999, these findings suggested that ileal interposition might 
be used as a treatment for T2D.56 Fast and permanent improvements in glucose control were 
observed in patients immediately after bariatric surgery, and surgery eliminated the need for 
glycaemia-controlling drugs in most cases.57,58 The beneficial effects of bariatric surgery on 
glycaemic control also depend on the duration of disease59 and the type of surgical 
intervention; interventions based solely on stomach restriction, such as adjustable gastric 
bands, proved to be less effective in improving T2D than procedures involving substantial 
amounts of intestinal bypass55,60,61 or significant increases in digestive transit speed, such as 
vertical gastrectomy.62,63 
Vertical gastrectomy is aimed mainly at achieving weight loss. It is a restrictive 
procedure due to the significant reduction in stomach reservoir capacity; moreover, it is 
considered a metabolic procedure, as it results in reduced circulating levels of the orexigenic 
hormone ghrelin, which is produced at the fundus and greater curvature of the stomach.62,63 
The good long-term postoperative64 glycaemic control achieved by vertical gastrectomy63 
might be due to the arrival of incompletely digested food at the distal ileum as a result of 
increased voiding speed after surgery, which in turn results in increased GLP-1 secretion by L-
cells.66 
Ileal interposition has frequently been performed in obese and non-obese humans; 
however, it is never performed in isolation. Promising results were recently obtained in 
humans using techniques combining vertical gastrectomy with the interposition of a segment 
of distal ileum in the trajectory of the proximal jejunum.67-72 This procedure can induce early 
satiety along with benefits to glucidic metabolism and cause short- and long-term weight loss. 
In non-obese diabetic patients, vertical gastrectomy combined with ileal interposition 
effectively controlled T2D.67-71 Analysis of the effects of vertical gastrectomy combined with 
ileal interposition on humans 6 and 18 months after the procedure demonstrated T2D 
remission in 80% of patients, who were freed from treatment with hypoglycaemic agents or 
diet. The remaining 20% of patients showed significant improvement despite the need to 
continue oral treatment (Tinoco, 2011).72 
Despite these findings, however, there is a conceptual problem in proposing to 
perform vertical gastrectomy in non-obese diabetic patients: the metabolic benefits reported 
in the literature67-22 were probably due almost exclusively to ileal interposition rather than to 
the partial gastric restriction procedure (vertical gastrectomy). 
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The early postoperative improvement in glucose metabolism observed in obese and 
diabetic patients subjected to vertical gastrectomy alone63 is most likely due to the increase in 
intestinal transit speed induced by intervention,66 which favours quicker arrival of undigested 
food to the terminal ileum, where it stimulates L-cells to produce endogenous GLP-1. We 
conclude that in these non-obese patients with glucidic dysmetabolism, vertical gastrectomy 
improves glucose metabolism, but this effect is only due to the acceleration of gastrointestinal 
transit, which causes incompletely digested food to arrive at the terminal ileum, where it 
triggers GLP-1 production by L-cells. Other consequences of vertical gastrectomy, such as the 
restriction caused by making the gastric reservoir a small-calibre tube, and the anorexigenic 
effect caused by reducing levels of the orexigenic hormone ghrelin,63 arise from the removal of 
the fundus and greater curvature of the stomach, where X/A-type neuroendocrine cells are 
more concentrated. However, vertical gastrectomy is a major surgical procedure that is not 
without significant complications, such as torpid evolution of fistulas and reflux esophagitis. 
There is no reason to apply this procedure to non-obese diabetic patients, in whom isolated 
ileal interposition may be highly effective. Ileal interposition in rats involves placing a 10- to 20-
cm segment of distal ileum with its nerves and vessels intact into the proximal jejunum,73 
resulting in significant hyperplasia, hypertrophy, and even full “jejunisation” of the transposed 
ileum.74-78 
Isolated ileal interposition proved efficacious in correcting dysmetabolism in several 
studies of experimental animals;51,79,80 however, in the context of bariatric and metabolic 
surgery, this surgical modality involving only ileal interposition has not been assessed in 
humans. 
Increased synthesis and release of GLP-1 can be attributed to increased stimulation of 
L-cells located in the interposed ileum segment in response to the presence of a greater 
amount of partially digested food, resulting in direct effects on glucidic metabolism (Patriti et 
al., 2007).81 Serum levels of GLP-1 increase in response to alimentary stimulation, resulting in a 
satiating effect on the central nervous system,82 reduced fat absorption by the gastrointestinal 
tract,83 and reduced gastric84 and intestinal motility.85 The most remarkable effects of GLP-1 
are reduced peripheral insulin resistance, decreased apoptosis of pancreatic beta cells, 
increased differentiation of primitive pancreatic canaliculus cells into adult beta cells, and 
increased proliferation of beta cells.86,87 
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GLP-1 is the incretin hormone most associated with the antidiabetic effects of bariatric 
surgery. Stimulation of ileal L-cells to cleave proglucagon and release GLP-1 seems to be the 
most effective means of inducing the incretin effect in diabetic patients subjected to bariatric 
surgery. Several techniques might be applied to achieve this effect. All of these techniques are 
derived from the hindgut theory, which states that contact of partially digested food with the 
ileum corrects the deleterious effects of “empty ileum syndrome” caused by the lack of L-cell 
stimulation.61,81,88 The results of the simple interposition of an ileum segment into the proximal 
segments of the small intestine are the strongest arguments supporting this hypothesis. A 
study of interposition in experimental animals subjected to a model of diet-induced obesity 
showed a significant increase in GLP-1 levels (Strader, 2006).52 Similarly, interposition of a 50-
cm ileum segment distal to Treitz’s angle in combination with vertical gastrectomy resulted in 
improved diabetes symptoms in a clinical trial.89 
In addition to the “ileal brake” (a reaction that decreases proximal gastrointestinal 
transit motility and enterohormone90,91 production following ileal interposition surgery), ileal 
interposition also improved glucose tolerance in experimental, euglycaemic rats.52,92 
These findings suggest that isolated ileal interposition might be a valid alternative for 
the treatment of diabetes. Due to the intestines’ great capacity for adaptation, further 
research is necessary to justify ileal interposition as a surgical treatment for diabetes. 
Specifically, studies addressing the ability of interposed ileum L-cells to continue to 
differentiate with a density similar to intact ileum; to fulfil their functions, including GLP-1 
production, over time; and to contribute to the metabolic control of glucose levels will be 
necessary.  
This project evaluated the effects of a surgical technique that interfered with the 
host’s enteroendocrine function and investigated the histological changes in the mucosa of 
intestinal L cells in a segment of distal ileum that was interposed with the proximal jejunum in 
rats. 
 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.6
68
3.
1 
: P
os
te
d 
11
 D
ec
 2
01
1
12 
 
2. METHOD 
2.1 Sample 
Forty 8-week old male Wistar-EPM1 rats (Rattus norvegicus albinus) of varying weights 
were used in the present study. The rats were provided by the Center for the Development of 
Medical and Biological Experimental Models (Centro de Desenvolvimento de Modelos 
Experimentais para Medicina e Biologia - CEDEME) – Federal University of São Paulo – Paulista 
School of Medicine (Universidade Federal de São Paulo – Escola Paulista de Medicina - 
UNIFESP-EPM). 
The animals were transferred to the Biophysics Vivarium and housed in collective 
cages at a controlled room temperature of 23  2C with a relative humidity of 55  15% and a 
12-hour light / dark cycle (6 am / 6 pm). The animals were transferred in installments to 
provide different aged groups for follow-up examinations in the animal housing facility. 
Two 12-week old animals were separated for surgeries and randomly distributed into 2 
groups: the Interposition Group (TG) was subjected to ileal interposition, and the Sham Group 
(SG) was subjected to sham operations.  
A third group, the Control Group (CG), included animals that were not subjected to 
surgery.  
All animals were followed until the 60th postoperative day (PO), and they were 
sacrificed according to the organogram (Figure 2).  
 
 
Figure 2 – Organogram representing the distribution of animals into 3 separate groups.  
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2.2 Experimental procedures 
2.2.1 Diet 
The animals received a normocaloric (4.5 Kcal/g) and normolipidic diet that contained 
10% fat, 20% protein and 70% carbohydrates ad libitum (Nuvilab CR-1,  Nuvital Nutrientes SA) 
throughout the study. 
 
2.2.2 Anesthesia 
A dissociative general anesthetic, 20 mg/kg Zoletil® 50 (tiletamine + zolazepam) and 
0.025 mg/kg fentanyl, was simultaneously injected intramuscularly prior to surgical 
interventions.93 The animals maintained spontaneous ventilation throughout the procedures, 
and the anesthetic plane was controlled using periodic evaluations of auricular and interdigital 
reflexes, which should be absent, every 45 minutes. Anesthesia was complemented with 1/3 of 
the initial anesthetic dose when these reflexes reappeared.93 
  
2.2.3 Surgical procedures 
Two rats were separated and randomly distributed into the TG or SG. Only water was 
provided to the animals for 6 hours prior to surgical procedures.  
The anesthetized animals were placed in a dorsal decubitus position on the operating 
table, and their paws and tails were bound with tape. The skin in the abdominal region was 
treated with chlorhexidine in an aqueous vehicle. The fur was not shaved.  
The abdominal region was covered with a fenestrated sterile surgical drape (Figure 3), 
and a medial longitudinal surgical incision approximately 5 cm in length was made in the 
abdominal wall using a #15 disposable scalpel blade (Figure 4). 
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Figure 3 – Anesthetized animal in the dorsal decubitus position on the operating table with a fenestrated surgical 
drape over the abdominal region.  
 
 
Figure 4 – Medial longitudinal incision approximately 5 cm in length in the abdominal wall. 
The cecum was initially identified and exposed (Figure 5) with the terminal ileum. The 
small intestine was sectioned perpendicularly 4 cm and 5 cm from the ileocecal transition in 
both surgical intervention groups to remove a 1-cm segment of the ileum for histological 
analysis.  
 
Figure 5 – Identification and exposure of the cecum and terminal ileum.  
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The ileum was sectioned perpendicularly 5 cm and 15 cm from the ileocecal transition 
in the TG to separate a 10-cm segment (Figure 6A). This segment was wrapped in gauze that 
was moistened with a warm solution of 0.9% sodium chloride. The continuity of the digestive 
tract was restored by anastomosis of the remaining ileal segments. The jejunum was sectioned 
5 cm from the duodenojejunal transition. The previously separated segment of the distal ileum 
was interposed with the sectioned segments of the jejunum in an isoperistaltic position (Figure 
6B). 
 
Figure 6 – A) Schematic illustration of the intestinal sections and isolated ileal segments (in black) to be interposed. 
B) Schematic illustration of the anastomosed distal ileum and interposed ileal segment (in black) that was 
anastomosed in the proximal segments of the jejunum. 
  
 The intestine was sectioned perpendicularly 5 cm and 15 cm from the ileocecal 
transition and 5 cm from the duodenojejunal transition in the SG. The digestive tract was 
immediately reconstructed using termino-terminal anastomosis. A 1-cm segment was removed 
from the distal ileum for histological and molecular biology analyses. All intestinal 
anastomoses were termino-terminal using 6 separate 7-0 polypropylene sutures that were 
premounted in a cylindrical needle (Figure 7).  
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Figure 7 – Termino-terminal intestinal anastomoses. 
 
Abdominal wall closure was performed using a continuous suture en bloc of the 
parietal peritoneum, muscular layer and aponeurosis using a 4-0 polyglactin suture that was 
premounted in a cylindrical needle. Continuous suture was performed on the skin using a 4-0 
polyglactin that was premounted in a cylindrical needle using reverse stitches.  
Hydration was performed at the end of the surgery using a subcutaneous injection of a 
0.5% saline solution in the dorsum of the animals at a dose of 10 ml/kg body weight.  
2.2.4 Postoperative evolution  
The animals were observed until they fully recovered from anesthesia. The animals 
were subsequently placed in individual cages and maintained in the shelter room of the 
Biophysics Vivarium under the same preoperative environmental conditions. 
Diet and water ad libitum were reintroduced after recovery from anesthesia.  
Operated animals were monitored and assessed until the 60th postoperative (PO) day, 
which corresponded to 8 PO weeks and 20 weeks of age. These assessments investigated the 
long-term effects of surgery because 60 days in a rat correlates to approximately 3 years in 
humans. The animals in the CG were also euthanized at 20 weeks of age. 
2.2.5 Euthanasia 
Euthanasia was performed by decapitation as directed by the Brazilian College of 
Animal Experimentation (COBEA) on the 60th PO day (8 PO weeks and 20 weeks of age) in the 
TG and SG and at 16 weeks of age in the CG.  
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2.2.6 Histology – Optical microscopy and immunohistochemistry  
The following tissues were collected during surgery for histological analysis: 
a) Segment of the proximal jejunum – Segment JE 1 (jejunum, moment 1); 
b) Segment of the distal ileum – Segment IL 1 (ileum, moment 1). 
The following tissues were collected for histological analysis after euthanasia: 
c) Interposed segment in the TG and the corresponding segment in the SG – Segment 
T 2 (interposed segment, moment 2); 
d) Segment of the jejunum proximal to the ileojejunal anastomosis in the TG and the 
jejunojejunal anastomosis in the SG – Segment JE 2 (jejunum, moment 2); 
e) Segment of the ileum distal to the ileoileal anastomosis – Segment IL 2 (ileum, 
moment 2). 
Histological sections for light microscopy were fixed for 12 to 24 hours in 10% buffered 
formaldehyde with monobasic sodium phosphate, dibasic sodium phosphate and NaCl in a 
volume that was 20 times greater than the volume of the tissue. Five 1-hour baths were 
performed in 100% ethyl alcohol for dehydration followed by 2 1-hour baths in xylene to 
promote tissue diaphanousness. Histological sections were processed for liquid paraffin 
embedding at 58°C in 2 1-hour baths. 
The histological sections were sent to the inclusion center for the preparation of the 
block. The inclusion center opened the cassettes, and the material was placed in a metal mold. 
Additional paraffin and ice were added, and the slides were subjected to histological sectioning 
in a rotary microtome at a thickness of 3 m. The slices were placed on silanized slides for 
immunohistochemistry. The slides were placed in an oven for 20 minutes for tissue section 
adhesion. 
The slides were crafted and stained using an anti-GLP-1 polyclonal antibody (Code 
AB26278 from Abcam, specific for immunohistochemical analysis). 
The histological sections were fixed in 10% buffered formaldehyde for 24 hours and 
processed for paraffin embedding. The sections were sliced using a Minot microtome at a 
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thickness of 5 mm and placed on slides that were previously treated with 5% silane. The slides 
containing the sections were subjected to the following protocol: 
a) Deparaffinization: the slides were incubated in a laboratory oven at 60°C for 12 
hours to improve tissue adhesion and deparaffinized in three 5-minute xylene baths at room 
temperature. 
b) Hydration: the slides were immersed twice in absolute ethanol for 5 minutes and 
washed with running water for 2 minutes to hydrate the sections.  
c) Antigen retrieval: the slides were placed in a 10 mM sodium citrate solution, pH 6.0, 
for 30 minutes in a steamer (95°C). The slides were cooled to room temperature for 20 
minutes and washed with 0.05 M PBS (phosphate-buffered saline), pH 7.4, 3 times for 3 
minutes each. 
d) Blocking of endogenous peroxidase: the slides were incubated 4 times in 3% 
hydrogen peroxide for 5 minutes and washed in running water and PBS, pH 7.4, 3 times for 3 
minutes.  
e) Blocking of nonspecific sites: the slides were incubated in PBS, pH 7.4, containing 1% 
BSA (bovine serum albumin) for 30 minutes at room temperature.  
f) Primary antibody binding: the slides were incubated with primary antibodies diluted 
in PBS + 1% BSA at a titration that was predetermined by the manufacturer in a moist chamber 
at 4ºC from 4 pm to 6 pm. The slides were subsequently washed 3 times in PBS, pH 7.4. 
g) Biotinylated secondary antibody binding: the sections were incubated with a biotin-
conjugated secondary antibody from the Dako LSAB kit for 30 minutes at room temperature in 
a moist chamber. The slides were washed 3 times in PBS, pH 7.4, and incubated in the Dako 
amplification kit (streptavidin conjugated to peroxidase) for 30 minutes. The slides were 
washed 3 times in PBS buffer, pH 7.4.  
h) Visualization: the sections were covered with a solution of chromogen 3,3’-
diaminobenzidine (liquid DAB). 
i) Counterstaining: the sections were washed in running water for 5 minutes and 
counterstained with Harris hematoxylin for 20 seconds. 
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j) Dehydration and mounting: the slides were washed in running water for 10 minutes, 
immersed 4 times in absolute ethanol and immersed 3 times in xylene. The slides were 
mounted with Ettelan® mounting medium, coverslipped and identified.  
The appearance of brownish staining indicated a positive result. Immunostaining was 
assessed using image representation through a computer system that consisted of a light 
microscope (Carl Zeiss) adapted to a high-resolution camera (Carl Zeiss Axiocam MRC) and a 
color video monitor (Samsung®). Images were captured using the QCapture Pro® image 
analysis program.  
2.2.7 Capturing, editing, image selection, cell counting method and the technique for 
measuring crypt area  
Immunostaining was assessed using image representation through a computer system 
that included a light microscope (Carl Zeiss) adapted to a high-resolution camera (Carl Zeiss 
Axiocam MRC) and a color video monitor (Samsung®). Histological sections were assessed at 
400X, and photomicrographs were taken sequentially around the intestinal perimeter using 
the QCapture Pro® software (QImaging Corporate Headquarters, Surrey, Canada) on 
equipment in the Department of Pathology, UNIFESP/EPM. 
The photomicrographs were sequentially edited using Adobe Photoshop CS4® 
software. The area of the intestinal crypts was selected and isolated (Figures 8 and 9).  
The identification and manual quantification of positively stained cells (cells L – brown 
staining) and measurement of the studied area (crypts) were performed using the Image J® 
program for image processing and analysis (Research Services Branch, National Institute of 
Mental Health, Bethesda, Maryland, USA). 
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Figure 8 – A) Photomicrograph of a histological section of the jejunum at 400X magnification, obtained with the 
QCapture Pro
®
 software. B) Same photomicrograph after editing in Adobe Photoshop CS4®; the intestinal crypt area 
was selected and isolated. 
 
 
 
Figure 9 – A) Photomicrograph of a histological section of the ileum at 400X magnification. B) Same 
photomicrograph after editing in Adobe Photoshop CS4
®
; the intestinal crypt area was selected and isolated. 
 
2.2.8 Study parameters   
The following data were used as study parameters:  
a) Calculation of the ratio between the number of L cells and the area of the measured 
crypts at all time points and in all groups.  
b) Comparison between groups at each time point.  
c) Comparison between 2 time points in the same group subjected to surgical 
intervention (prior to and after surgery).  
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3. RESULTS 
 These results only refer to this Scientific Initiation Project. Data on animal weight, food 
intake, intestinal measurements, biochemical tests and histological staining with hematoxylin-
eosin are included in other research at the undergraduate and graduate levels. 
The relationship between the number of identified L cells and the measured crypt area 
was calculated to obtain the number of L cells per square micrometers. 
The data were plotted and analyzed using Excel (Office 2007) and the Statistical 
Package for Social Sciences (SPSS) version 17.0 for Windows®.  
The statistical analysis was initially performed in a descriptive manner. For quantitative 
(numerical) variables, summary measures, such as the mean, median, minimum, maximum 
and standard deviation, were calculated, and box plots and individual profile graphs were 
generated. 
The inferential analyses that were used to confirm or refute the data in the descriptive 
analysis included the following: 
a) Analysis of variance (ANOVA) for comparisons between the three groups (TG, SG 
and CG); 
b) Student’s t test for comparisons between the surgical groups (TG and SG) prior to 
and after surgical intervention; and 
c) Paired Student’s t test for comparisons within the surgical group (TG and SG) at the 
two evaluated time points (prior to and after surgery).   
A 5% level of significance was used for all conclusions that were obtained through the 
inferential analyses.  
3.1 Before ileal interposition  
The following data were observed prior to surgical intervention:  
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Table 1 – L cells/area of the crypt ratio (x100,000) in the intestinal segment of the jejunum in the Interposition and 
Sham groups. 
Group N Average Standard 
deviation 
Standard error P
* 
Sham 14 1,31970 0,508007 0,135771 
0,809 
Interposition 10 1,26010 0,688010 0,217568 
*
t test 
 
 
 
Figure 10 – Box plot showing the L cells/area of the crypt ratio (x100,000) in the intestinal segment of the jejunum 
in the Interposition and Sham groups.   
 
 
 
Table 2 - L cells/area of the crypt ratio (x100,000) in the intestinal segment of the ileum in the Interposition and 
Sham groups.  
 
Group N Average Standard deviation Standard error P
* 
Sham 14 2,34835 0,720569 0,192580 
0,060 
Interposition 11 2,91980 0,715171 0,215632 
*
t test 
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Figure 11 - Box plot showing the L cells/area of the crypt ratio (x100,000) in the intestinal segment of the ileum in 
the Interposition and Sham groups. 
 
 
3.2 After ileal interposition 
Table 3 - L cells/area of the crypt ratio (x100,000) in the intestinal segment of the jejunum in the Control, Sham and 
Interposition groups. 
Group N Average Standard 
deviation 
Standard error P
* 
Control 15 1,24397 0,581792 0,150218 
0,707 Sham 14 1,10346 0,416211 0,111237 
Interposition 10 1,12133 0,407075 0,128728 
*
ANOVA test 
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Figure 12 – Box plot showing the L cells/area of the crypt ratio (x100,000) in the intestinal segment of the jejunum 
in the Control, Sham and Interposition groups.  
 
 
Table 4 - L cells/area of the crypt ratio (x100,000) in the intestinal segment of the ileum in the Control, Sham and 
Interposition groups.  
Group N Average Standard deviation Standard error P
* 
Control 15 3,37928 1,163020 0,300291 
0,779 Sham 14 3,12727 1,000859 0,267491 
Interposition 11 3,11448 1,180884 0,356050 
*
ANOVA test 
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Figure 13 – Box plot showing the L cells/area of the crypt ratio (x100,000) in the intestinal segment of the ileum in 
the Control, Sham and Interposition groups. 
 
 
Table 5 - L cells/area of the crypt ratio (x100,000) in the simulated intestinal segment of the interposed ileum and a 
segment of the interposed ileum in the Sham and Interposition groups, respectively.  
Group N Average Standard deviation Standard error P
* 
Sham 13 2,87171 1,087292 0,301561 
0,307 
Interposition 10 3,30340 0,814976 0,257718 
*
ANOVA test 
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Figure 14 – Box plot showing the L cells/area of the crypt ratio (x100,000) in the simulated intestinal segment of the 
interposed ileum and a segment of the interposed ileum in the Sham and Interposition groups, respectively. 
 
 
Table 6 - L cells/area of the crypt ratio (x100,000) in intestinal segments in the Sham group prior to and after 
surgical intervention.   
Intestinal segment N Average Standard deviation Standard error P
* 
Jejunum prior to ileal 
interposition 
14 1,31970 0,508007 0,135771 
0,226 
Jejunum after ileal 
interposition 
14 1,10346 0,416211 0,111237 
Ileum prior to ileal 
interposition 
14 2,34835 0,720569 0,192580 
0,008 
Ileum after ileal 
interposition 
14 3,12727 1,000859 0,267491 
Simulated interposed 
ileum prior to ileal 
interposition 
13 2,33874 0,749057 0,207751 
0,194 
Simulated interposed 
Ileum after ileal 
interposition 
13 2,87171 1,087292 0,301561 
*
paired-t test 
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Table 7 - L cells/area of the crypt ratio (x100,000) in intestinal segments in the Interposition group prior to and after 
surgical intervention.   
Intestinal segment N Average Standard deviation Standard error P
* 
Jejunum prior to ileal 
interposition 
9 1,26338 0,729662 0,243221 
0,618 
Jejunum after ileal 
interposition 
9 1,10299 0,427361 0,142454 
Ileum prior to ileal 
interposition 
11 2,91980 0,715171 0,215632 
0,635 
Ileum after ileal 
interposition 
11 3,11448 1,180884 0,356050 
Simulated interposed 
ileum prior to ileal 
interposition 
10 2,89469 0,748729 0,236769 
0,152 
Interposed Ileum after 
ileal interposition 
10 3,30340 0,814976 0,257718 
*
paired-t test 
 
 
 
Figure 15 – Average profile of the L cells/area of the crypt ratio (x100,000) in the intestinal segment of jejunum in 
the Sham (1 – in blue) and Interposition (2 – in red) groups prior to and after surgical intervention. 
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Figure 16 – Average profile of the L cells/area of the crypt ratio (x100,000) in the intestinal segment of the ileum in 
the Sham (1 – in blue) and Interposition (2 – in red) groups prior to and after surgical intervention. 
 
 
 
Figure 17 – Average profile of the L cells/area of the crypt ratio (x100,000) in a simulated intestinal segment of the 
interposed ileum (Sham Group – 1 – in blue) and an interposed segment (Interposition Group – 2 – in red) prior to 
and after surgical intervention. 
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4. DISCUSSION 
This project evaluated histological alterations following surgical intervention for 
metabolic and weight purposes, which provides additional information on the 
pathophysiological aspects of these surgeries. In addition, this study proposed bariatric and 
metabolic surgical techniques with reduced technical complexity without the isolation or 
removal of segments. An understanding of the morphological alterations that result from the 
modification of the gastrointestinal anatomy, as determined by the surgical technique, is 
essential. Specifically, an investigation of the enterohormone-producing cells, the L cells, that 
produce GLP-1 is required. 
The TG demonstrated an L cells/area of crypt ratio that was similar to the SG for both 
intestinal segments of the jejunum and ileum prior to ileal interposition (Tables 1 and 2; 
Figures 15 and 16). This relationship was expected because all of the animals were in the same 
sample with no prior intervention or procedure. These animals served as comparisons for the 
after ileal interposition time point to avoid the possibility that this ratio differed significantly 
and independently from the proposed surgery between groups.  
Ileal interposition yielded the following results. The L cells/area of the crypt ratio in the 
intestinal segment of the jejunum remained similar in the CG, SG and TG with no significant 
differences (Table 3 and Figure 15). The L cells/area of the crypt ratio in the intestinal segment 
of the ileum remained similar in the CG, SG and TG with no significant differences (Table 4 and 
Figure 16). The L cells/area of the crypt ratio in the intestinal segment that corresponded to 
the interposed ileum and the intestinal segment of the interposed ileum were similar in the 
CG, SG and TG with no significant differences (Table 5 and Figure 17). 
A comparison of the L cells/area of the crypt ratio in intestinal segments of the 
jejunum and ileum with the interposed segment in the SG prior to and after surgical 
intervention revealed that this ratio remained similar with no significant differences. However, 
the L cells/area of the crypt ratio was increased in the distal segment of the ileum after surgical 
intervention (Table 6).  
The L cells/area of the crypt ratio in intestinal segments of the jejunum, ileum and the 
interposed ileum in the TG remained similar prior to and after surgical intervention with no 
significant differences (Table 7).  
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The individual average profiles of the L cells/area of the crypt ratios were maintained 
over time in the intestinal segments of the jejunum and the simulated intestinal segment of 
the ileum to the interposed segment and the interposed ileal segment in the TG and SG, 
respectively (Figures 15 and 16). However, the average profile of the L cells/area of the crypt 
ratio in the intestinal segment of the ileum was increased in the SG.  
No significant alterations in the L cells/area of the crypt ratio were noted in the 
intestinal segment at any time after ileal interposition, except for the ileal segment after 
surgical intervention in the SG. 
The present study demonstrated that intestinal segments maintained their 
characteristics after a surgical procedure in which a segment of distal ileum was interposed to 
a region of the proximal jejunum. The segment of interposed ileum maintained its histological, 
and likely endocrine, characteristics with belatedly active L cells as well as the L cells/area of 
the crypt ratio in the interposed and other intestinal segments prior to and after ileal 
interposition. 
Therefore, the interposition of a distal ileum segment to a region of the proximal 
jejunum or surgical procedures that shorten the path of ingested food through the digestive 
tract allow for a greater contact of the L cells of the distal small intestines with nutrients, 
which stimulates the early release of incretin hormones. 85,88,81,94,95,91 This result may explain 
the improvements in the clinical and laboratorial conditions of patients with metabolic 
syndrome who undergo these procedures.  
Moreover, bariatric and metabolic surgical techniques are viable and feasible for the 
treatment of metabolic diseases (mainly diabetes96-98) due to their reduced technical 
complexity, a reduction in the isolated and resected segments, fewer complications than other 
bariatric procedures99 and lower costs.  However,  the most appropriate surgical techniques for 
each patient should be determined individually because the expected and obtained results 
depend on the technique that is used.100 
 
5. CONCLUSION 
 No structural and histological changes in intestinal L cells in the interposed intestinal 
segment and other intestinal segments were noted after ileal interposition surgery in normal 
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rats. Therefore, the endocrine characteristics of these cells were likely maintained, which 
justifies the use of bariatric and metabolic surgical techniques for the treatment of metabolic 
diseases, especially diabetes. 
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